Bioventus beats Q4 revenue estimates on strong demand for pain treatments and surgical solutions

Bioventus

05/03/2026 12:09

Overview

Medical device firm's Q4 revenue rose 2.8%, beating analyst expectations

Adjusted EPS for Q4 beat analyst expectations

Company generated $38 mln in Q4 cash from operations, up 97% yr/yr

Outlook

Bioventus expects 2026 net sales of $600 mln to $610 mln

Company anticipates 2026 adjusted EPS of $0.73 to $0.77

Bioventus forecasts 2026 cash from operations of $82 mln to $87 mln

Result Drivers

PAIN TREATMENTS - Strong demand for hyaluronic acid therapies for knee osteoarthritis drove 15.1% revenue growth in Pain Treatments

SURGICAL SOLUTIONS - Higher U.S. demand for Bone Graft Substitutes led to 3.4% revenue growth in Surgical Solutions

DIVESTITURE IMPACT - Revenue growth was impacted by the prior-year divestiture of the Advanced Rehabilitation Business

Company press release: ID:nGNX7xmQXG

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Beat
$157.9 mln
$154.85 mln (4 Analysts)
Q4 Adjusted EPS
Beat
$0.24
$0.22 (3 Analysts)
Q4 Adjusted EBITDA
$36.7 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for Bioventus Inc is $15.00, about 77.1% above its March 4 closing price of $8.47

The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 10 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)